Literature DB >> 28574572

Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress.

Afsane Bahrami1,2, Majid Khazaei3, Seyed Mahdi Hassanian4,5, Soodabeh ShahidSales6, Mona Joudi-Mashhad6, Mina Maftouh5, Mir Hadi Jazayeri7,8, Mohammad Reza Parizade5, Gordon A Ferns9, Amir Avan5,6.   

Abstract

Colorectal cancer (CC) is often diagnosed at a late stage when tumor metastasis may have already occurred. Current treatments are often ineffective in metastatic disease, and consequently late diagnosis is often associated with poor outcomes in CC. Alternative strategies are therefore urgently required. An interaction between epithelial cancer cells and their tissue microenvironment is a contributor to metastasis, and therefore recent studies are beginning to focus on the properties of the tumor microenvironment and the mechanism by which the metastatic cells exploit the tumor microenvironment for survival, immune evasion, and growth. We have reviewed the development of the combined therapeutic approaches that have focused on targeting the microenvironment of CC.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  colorectal cancer; extracellular matrix; fibroblast; microenvironment

Mesh:

Year:  2017        PMID: 28574572     DOI: 10.1002/jcp.26041

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Nuclear-localized costimulatory molecule 4-1BBL promotes colon cancer cell proliferation and migration by regulating nuclear Gsk3β, and is linked to the poor outcomes associated with colon cancer.

Authors:  Yan Ge; Wei Chen; Xueguang Zhang; Haiyan Wang; Juanjuan Cui; Yue Liu; Songwen Ju; Xinxin Tian; Songguang Ju
Journal:  Cell Cycle       Date:  2020-01-28       Impact factor: 4.534

2.  Exosomal miR-30a and miR-222 derived from colon cancer mesenchymal stem cells promote the tumorigenicity of colon cancer through targeting MIA3.

Authors:  Qiong Du; Xuan Ye; Sheng-Rong Lu; Huan Li; Hong-Yue Liu; Qing Zhai; Bo Yu
Journal:  J Gastrointest Oncol       Date:  2021-02

Review 3.  Current Strategies to Enhance Anti-Tumour Immunity.

Authors:  Katherine W Cook; Lindy G Durrant; Victoria A Brentville
Journal:  Biomedicines       Date:  2018-03-23

4.  Integrin α5 subunit is required for the tumor supportive role of fibroblasts in colorectal adenocarcinoma and serves as a potential stroma prognostic marker.

Authors:  Ling Lu; Ruting Xie; Rong Wei; Chunmiao Cai; Dexi Bi; Dingzi Yin; Hu Liu; Jiayi Zheng; Youhua Zhang; Feifei Song; Yaohui Gao; Linhua Tan; Qing Wei; Huanlong Qin
Journal:  Mol Oncol       Date:  2019-11-06       Impact factor: 6.603

5.  AFF4 Predicts the Prognosis of Colorectal Cancer Patients and Suppresses Colorectal Cancer Metastasis via Promoting CDH1 Expression.

Authors:  Yi Fang; Hua Cao; Xiaoyong Gong; Yanqing Chen; Yugang Zhuang; Shuqin Zhou; Yuanzhuo Chen; Yimei Jiang; Xiaopin Ji; Hu Peng; Xiaoqian Jing
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

Review 6.  The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches.

Authors:  Narges Zafari; Fatemeh Khosravi; Zahra Rezaee; Sahar Esfandyari; Mohamad Bahiraei; Afshin Bahramy; Gordon A Ferns; Amir Avan
Journal:  J Clin Lab Anal       Date:  2022-07-08       Impact factor: 3.124

7.  CircCDR1as upregulates autophagy under hypoxia to promote tumor cell survival via AKT/ERK½/mTOR signaling pathways in oral squamous cell carcinomas.

Authors:  Ling Gao; Zhi-Chao Dou; Wen-Hao Ren; Shao-Ming Li; Xiao Liang; Ke-Qian Zhi
Journal:  Cell Death Dis       Date:  2019-10-03       Impact factor: 8.469

8.  A nomogram to predict vascular invasion before resection of colorectal cancer.

Authors:  Weishun Xie; Jungang Liu; Xiaoliang Huang; Guo Wu; Franco Jeen; Shaomei Chen; Chuqiao Zhang; Wenkang Yang; Chan Li; Zhengtian Li; Lianying Ge; Weizhong Tang
Journal:  Oncol Lett       Date:  2019-09-30       Impact factor: 2.967

9.  Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.

Authors:  Simeng Wang; Xinrui Zhou; Zekun Zeng; Mengjun Sui; Lihong Chen; Chao Feng; Chen Huang; Qi Yang; Meiju Ji; Peng Hou
Journal:  J Nanobiotechnology       Date:  2021-10-02       Impact factor: 10.435

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.